Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Research library

Released: · Last reviewed:

Pending medical review. These summaries reflect widely reported findings from foundational trials of FDA-approved semaglutide and tirzepatide products. The section is excluded from search indexing until a named medical reviewer confirms each summary and adds DOI, PMID, and ClinicalTrials.gov identifiers. No summary below applies to compounded formulations.

STEP 1

Product studied
semaglutide 2.4 mg weekly (Wegovy dose) — an FDA-approved product, not a compounded formulation
Design
Randomized, double-blind, placebo-controlled; ~1,960 adults with overweight or obesity without diabetes; 68 weeks
Headline finding
Mean weight loss of roughly 15% of body weight with semaglutide 2.4 mg plus lifestyle intervention versus ~2.4% with placebo; gastrointestinal effects were the most common adverse events.
Citations
DOI / PMID / NCT to be confirmed and added at medical review — identifiers are never printed from memory
Applicability
Results apply to the trialed FDA-approved product and doses; they do not establish outcomes for compounded, microdose, oral, ODT, or sublingual formulations.

SURMOUNT-1

Product studied
tirzepatide 5/10/15 mg weekly (Zepbound doses) — an FDA-approved product, not a compounded formulation
Design
Randomized, double-blind, placebo-controlled; ~2,540 adults with obesity without diabetes; 72 weeks
Headline finding
Dose-dependent mean weight loss reaching roughly 20–21% at the highest dose versus ~3% with placebo; gastrointestinal events most common, typically during dose escalation.
Citations
DOI / PMID / NCT to be confirmed and added at medical review — identifiers are never printed from memory
Applicability
Results apply to the trialed FDA-approved product and doses; they do not establish outcomes for compounded, microdose, oral, ODT, or sublingual formulations.

SELECT

Product studied
semaglutide 2.4 mg weekly — an FDA-approved product, not a compounded formulation
Design
Randomized, double-blind, placebo-controlled cardiovascular-outcomes trial; ~17,600 adults with established cardiovascular disease and overweight or obesity, without diabetes; multi-year follow-up
Headline finding
Approximately a 20% relative reduction in major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) versus placebo.
Citations
DOI / PMID / NCT to be confirmed and added at medical review — identifiers are never printed from memory
Applicability
Results apply to the trialed FDA-approved product and doses; they do not establish outcomes for compounded, microdose, oral, ODT, or sublingual formulations.

SURMOUNT-4

Product studied
tirzepatide, maximum tolerated dose — an FDA-approved product, not a compounded formulation
Design
Randomized-withdrawal design: open-label tirzepatide lead-in, then randomization to continued tirzepatide or placebo; 88 weeks total
Headline finding
Continuing tirzepatide produced further weight loss after the lead-in, while switching to placebo led to substantial regain of lost weight — central evidence on discontinuation and weight regain.
Citations
DOI / PMID / NCT to be confirmed and added at medical review — identifiers are never printed from memory
Applicability
Results apply to the trialed FDA-approved product and doses; they do not establish outcomes for compounded, microdose, oral, ODT, or sublingual formulations.

SURMOUNT-5

Product studied
tirzepatide vs semaglutide, head-to-head — an FDA-approved product, not a compounded formulation
Design
Randomized, open-label; adults with obesity without diabetes; 72 weeks; funded by Eli Lilly
Headline finding
Tirzepatide produced greater mean weight loss than semaglutide 2.4 mg (roughly 20% versus 14%), with broadly similar gastrointestinal adverse-event profiles; the open-label design and sponsor funding are relevant limitations.
Citations
DOI / PMID / NCT to be confirmed and added at medical review — identifiers are never printed from memory
Applicability
Results apply to the trialed FDA-approved product and doses; they do not establish outcomes for compounded, microdose, oral, ODT, or sublingual formulations.

Reported weight-loss outcomes across pivotal trials

Mean total body-weight reduction in pivotal obesity trials · FDA-approved products at studied doses · these figures do NOT transfer to compounded, microdose, oral, ODT, or sublingual formulations
STEP 1 — semaglutide 2.4mgSTEP 1 — semaglutide 2.4mg: 14.9% (68 weeks)14.9%SURMOUNT-1 — tirzepatide 15mgSURMOUNT-1 — tirzepatide 15mg: 20.9% (72 weeks)20.9%SURMOUNT-1 — tirzepatide 10mgSURMOUNT-1 — tirzepatide 10mg: 19.5% (72 weeks)19.5%SURMOUNT-5 — tirzepatide (h2h)SURMOUNT-5 — tirzepatide (h2h): 20.2% (72 weeks)20.2%SURMOUNT-5 — semaglutide (h2h)SURMOUNT-5 — semaglutide (h2h): 13.7% (72 weeks)13.7%

FDA-approved injectable products at studied doses. These outcomes do not transfer to compounded, microdose, or oral/sublingual formulations. Values pending citation confirmation at medical review.

View chart data as a table
Mean total body-weight reduction in pivotal obesity trials
Trial & productMean weight reductionDuration
STEP 1 — semaglutide 2.4mg14.9%68 weeks
SURMOUNT-1 — tirzepatide 15mg20.9%72 weeks
SURMOUNT-1 — tirzepatide 10mg19.5%72 weeks
SURMOUNT-5 — tirzepatide (h2h)20.2%72 weeks
SURMOUNT-5 — semaglutide (h2h)13.7%72 weeks

These are widely reported headline figures from the pivotal trials of the FDA-approved injectable products at their studied doses, shown for scientific context and pending medical-reviewer confirmation of each value with its DOI/PMID/NCT. They are not evidence for any compounded preparation, any sub-therapeutic "microdose," or any oral/sublingual route. Percentages are placebo-subtracted or total means as reported and will be finalized with citations at review.

Planned coverage

Remaining STEP and SURMOUNT trials; SUSTAIN and SURPASS diabetes programs; PIONEER and OASIS oral-semaglutide programs; FLOW, SUMMIT, SURMOUNT-OSA, and ESSENCE outcomes trials; discontinuation and weight-regain meta-analyses; body-composition, sarcopenia, and frailty evidence; compounded-product real-world studies with funding and design disclosures; and research-only pages for investigational agents (retatrutide, CagriSema, cagrilintide, survodutide, mazdutide, amycretin). Investigational agents receive no purchase, provider, ranking, compounding, or dosing content — retatrutide and cagrilintide are not FDA approved and are not lawfully available as compounded treatments.